论文部分内容阅读
目的:通过分析大剂量化疗(HDT)联合自体造血干细胞移植(ASCT)治疗淋巴瘤的临床体会,探究安全合理的动员和预处理方案,以进一步提高治疗的安全性和疗效。方法:对59例接受HDT联合ASCT治疗的淋巴瘤患者的资料进行回顾分析。结果:59例患者采集到足够数量的造血干细胞,预处理后接受ASCT并成功恢复造血。随访1~88个月(中位数26.3个月),47例患者无病生存1~88个月(中位数28.5个月),10例在移植后2~37个月死于肿瘤复发,1例移植后16个月死于深部霉菌感染,1例移植后9个月死于爆发性肝炎。结论:HDT联合ASCT与常规化疗有机结合可能是治疗淋巴瘤安全、有效的方法。
Objective: To analyze the clinical experience of high-dose chemotherapy (HDT) combined with autologous hematopoietic stem cell transplantation (ASCT) in the treatment of lymphoma and to explore the safe and rational mobilization and pretreatment programs to further improve the safety and efficacy of the treatment. Methods: The data of 59 patients with lymphoma treated by HDT combined with ASCT were retrospectively analyzed. RESULTS: A total of 59 patients had a sufficient number of hematopoietic stem cells collected. After pretreatment ASCT was performed and hematopoiesis was successfully restored. All the patients were followed up for 1-88 months (median 26.3 months), 47 patients survived for 1-88 months (median 28.5 months), 10 died of tumor recurrence 2-37 months after transplantation, One case died of a deep mold infection at 16 months after transplantation, and one case died of fulminant hepatitis at 9 months after transplantation. Conclusion: The combination of HDT and routine chemotherapy may be a safe and effective method for the treatment of lymphoma.